#Diagnostics11
AI blood test helps identify causes of dementia
Researchers report an AI-based blood test that can distinguish common causes of dementia from normal aging. The test uses a panel of blood proteins and showed strong agreement with brain autopsy results, but it needs more validation.
Photo by Lokesh B Masania, Unsplash
Blood biomarkers for inflammatory breast cancer
Researchers have found blood-based biomarkers that can distinguish inflammatory breast cancer (IBC) from other breast cancer types. Using a robust RNA method, the discovery could allow earlier detection, easier monitoring and help guide new treatments.
AI is changing basic health care in sub‑Saharan Africa
Artificial intelligence is already helping basic medical care in parts of sub‑Saharan Africa. Pilot projects in Kenya, Ghana and Rwanda show faster diagnosis, fewer wrong prescriptions and quicker delivery of blood and imaging results.
Lower mGlu5 receptor found across autistic adult brains
A study in The American Journal of Psychiatry found lower availability of a glutamate receptor called mGlu5 across the brains of autistic adults. Researchers used PET, MRI and EEG and say the result could affect future diagnosis and treatment.
Wearable 10‑Minute Antibody Sensors from University of Pittsburgh
Researchers at the University of Pittsburgh made a wearable biosensor that detects antibodies in interstitial fluid in 10 minutes without a blood draw. The tiny carbon nanotube sensors are highly sensitive and the work appears in Analytical Chemistry.
Study finds Abbott-Bioline malaria test gives many false negatives
A study on the Thailand–Myanmar border found the Abbott-Bioline rapid malaria test missed many infections. Researchers call it “not fit for purpose”; WHO and the manufacturer are reviewing the test and further studies are under way.
Rwanda strengthens response to Rift Valley Fever outbreak
Rwanda reported a second Rift Valley Fever outbreak near the Tanzania border and has increased surveillance and livestock vaccination. Officials say lack of rapid diagnostic tests slows detection, while a human vaccine candidate enters Phase II trials.
No more articles